| Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial K Fischer, J Bahlo, AM Fink, V Goede, CD Herling, P Cramer, ... Blood, The Journal of the American Society of Hematology 127 (2), 208-215, 2016 | 795 | 2016 |
| Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia MJ Kiel, T Velusamy, D Rolland, AA Sahasrabuddhe, F Chung, NG Bailey, ... Blood, The Journal of the American Society of Hematology 124 (9), 1460-1472, 2014 | 253 | 2014 |
| Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity KS Reiners, D Topolar, A Henke, VR Simhadri, J Kessler, M Sauer, ... Blood, The Journal of the American Society of Hematology 121 (18), 3658-3665, 2013 | 235 | 2013 |
| TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin M Herling, MA Teitell, RR Shen, LJ Medeiros, D Jones Blood 101 (12), 5007-5009, 2003 | 222 | 2003 |
| TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state M Herling, KA Patel, J Khalili, E Schlette, R Kobayashi, LJ Medeiros, ... Leukemia 20 (2), 280-285, 2006 | 203 | 2006 |
| A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories M Herling, JD Khoury, LBT Washington, M Duvic, MJ Keating, D Jones Blood 104 (2), 328-335, 2004 | 197 | 2004 |
| CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells M Herling, D Jones American journal of clinical pathology 127 (5), 687-700, 2007 | 190 | 2007 |
| Synthesis and selective anticancer activity of organochalcogen based redox catalysts M Doering, LA Ba, N Lilienthal, C Nicco, C Scherer, M Abbas, AAP Zada, ... Journal of medicinal chemistry 53 (19), 6954-6963, 2010 | 158 | 2010 |
| Differential Expression and Clinical Significance of Tyrosine-phosphorylated STAT3 in ALK+ and ALK− Anaplastic Large Cell Lymphoma JD Khoury, LJ Medeiros, GZ Rassidakis, MA Yared, P Tsioli, V Leventaki, ... Clinical cancer research 9 (10), 3692-3699, 2003 | 152 | 2003 |
| Drug-perturbation-based stratification of blood cancer S Dietrich, M Oleś, J Lu, L Sellner, S Anders, B Velten, B Wu, J Huellein, ... The Journal of clinical investigation 128 (1), 427-445, 2018 | 150 | 2018 |
| CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin’s disease: associations with presenting features and clinical outcome GZ Rassidakis, LJ Medeiros, S Viviani, V Bonfante, GP Nadali, ... Journal of Clinical Oncology 20 (5), 1278-1287, 2002 | 147 | 2002 |
| Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy CD Herling, M Klaumünzer, CK Rocha, J Altmüller, H Thiele, J Bahlo, ... Blood, The Journal of the American Society of Hematology 128 (3), 395-404, 2016 | 146 | 2016 |
| High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia M Herling, KA Patel, MA Teitell, M Konopleva, F Ravandi, R Kobayashi, ... Blood, The Journal of the American Society of Hematology 111 (1), 328-337, 2008 | 143 | 2008 |
| BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens GZ Rassidakis, LJ Medeiros, TP Vassilakopoulos, S Viviani, V Bonfante, ... Blood, The Journal of the American Society of Hematology 100 (12), 3935-3941, 2002 | 139 | 2002 |
| Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer L Meder, P Schuldt, M Thelen, A Schmitt, F Dietlein, S Klein, S Borchmann, ... Cancer research 78 (15), 4270-4281, 2018 | 134 | 2018 |
| Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage GZ Rassidakis, AH Sarris, M Herling, RJ Ford, F Cabanillas, ... The American journal of pathology 159 (2), 527-535, 2001 | 126 | 2001 |
| High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia M Herling, KA Patel, N Weit, N Lilienthal, M Hallek, MJ Keating, D Jones Blood, The Journal of the American Society of Hematology 114 (21), 4675-4686, 2009 | 124 | 2009 |
| Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor N Reinart, PH Nguyen, J Boucas, N Rosen, HM Kvasnicka, L Heukamp, ... Blood, The Journal of the American Society of Hematology 121 (5), 812-821, 2013 | 110 | 2013 |
| A PP4 holoenzyme balances physiological and oncogenic nuclear factor-kappa B signaling in T lymphocytes M Brechmann, T Mock, D Nickles, M Kiessling, N Weit, R Breuer, W Müller, ... Immunity 37 (4), 697-708, 2012 | 108 | 2012 |
| Combined radiofrequency thermal ablation and percutaneous cementoplasty treatment of a pathologic fracture O Schaefer, C Lohrmann, M Herling, P Uhrmeister, M Langer Journal of Vascular and Interventional Radiology 13 (10), 1047-1050, 2002 | 107 | 2002 |
Michael HallekUniversity of CologneVerified email at uni-koeln.de
